Javascript must be enabled to continue!
Antiviral Resistance Testing
View through CrossRef
Abstract
The number of antiviral drugs approved for clinical use has dramatically increased in the past 25 years. However, the use of the drugs may result in the development of resistance mutations in viral genes targeted for therapy. As a result, antiviral resistance testing is commonplace in many molecular diagnostic laboratories and has become a useful tool for the clinical management of viral infections that can be treated with antivirals. Antiviral resistance testing involves identification of the mutations using sequencing methods (genotyping) and determination of their effect on viral drug susceptibility using
in‐vitro
cell‐based assays (phenotyping). For viruses with well characterised resistance mutations, such as human immunodeficiency virus, genotypic methods that are fast and easier to perform are sufficient. However, phenotypic methods or a combination of both methods provide a comprehensive strategy for other viruses.
Key Concepts:
The majority of antiviral drugs target virus‐specific proteins important for viral replication.
Antiviral resistance develops via the emergence of mutations in viral genes targeted for therapy.
There are two main methods for the measurement of antiviral resistance namely, genotypic antiviral resistance testing and phenotypic drug susceptibility testing.
Genotypic antiviral resistance testing identifies mutations associated with drug resistance using sequencing techniques.
Genotypic interpretation systems (GISs) are rule‐based computational tools that rely on a database of sequence, clinical and laboratory information to translate the mutational pattern in amplified sequence into drug susceptibility levels using arbitrary scores.
Phenotypic drug susceptibility testing is a direct measure of the ability of a virus isolate to replicate in the presence of a specific drug using an
in‐vitro
cell culture system.
The clinical significance and utility of detecting minority drug resistance mutations present at less than 20% of the population has yet to be fully determined.
Title: Antiviral Resistance Testing
Description:
Abstract
The number of antiviral drugs approved for clinical use has dramatically increased in the past 25 years.
However, the use of the drugs may result in the development of resistance mutations in viral genes targeted for therapy.
As a result, antiviral resistance testing is commonplace in many molecular diagnostic laboratories and has become a useful tool for the clinical management of viral infections that can be treated with antivirals.
Antiviral resistance testing involves identification of the mutations using sequencing methods (genotyping) and determination of their effect on viral drug susceptibility using
in‐vitro
cell‐based assays (phenotyping).
For viruses with well characterised resistance mutations, such as human immunodeficiency virus, genotypic methods that are fast and easier to perform are sufficient.
However, phenotypic methods or a combination of both methods provide a comprehensive strategy for other viruses.
Key Concepts:
The majority of antiviral drugs target virus‐specific proteins important for viral replication.
Antiviral resistance develops via the emergence of mutations in viral genes targeted for therapy.
There are two main methods for the measurement of antiviral resistance namely, genotypic antiviral resistance testing and phenotypic drug susceptibility testing.
Genotypic antiviral resistance testing identifies mutations associated with drug resistance using sequencing techniques.
Genotypic interpretation systems (GISs) are rule‐based computational tools that rely on a database of sequence, clinical and laboratory information to translate the mutational pattern in amplified sequence into drug susceptibility levels using arbitrary scores.
Phenotypic drug susceptibility testing is a direct measure of the ability of a virus isolate to replicate in the presence of a specific drug using an
in‐vitro
cell culture system.
The clinical significance and utility of detecting minority drug resistance mutations present at less than 20% of the population has yet to be fully determined.
Related Results
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Evolution of Antimicrobial Resistance in Community vs. Hospital-Acquired Infections
Abstract
Introduction
Hospitals are high-risk environments for infections. Despite the global recognition of these pathogens, few studies compare microorganisms from community-acqu...
Network controllability analysis reveals the antiviral potential of Etravirine against Hepatitis E Virus infection
Network controllability analysis reveals the antiviral potential of Etravirine against Hepatitis E Virus infection
Abstract
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis in lower- and middle-income countries. HEV infection may lead to acute...
The association of prokaryotic antiviral systems and symbiotic phage communities in drinking water microbiomes
The association of prokaryotic antiviral systems and symbiotic phage communities in drinking water microbiomes
Abstract
Prokaryotic antiviral systems are important mediators for prokaryote-phage interactions, which have significant implications for the survival of prokaryotic...
Susceptibility Test Methods: Viruses
Susceptibility Test Methods: Viruses
Abstract
Testing for viral susceptibility, primarily via genotypic drug resistance mutation testing, is now standard practice for the management of viral infections for o...
Susceptibility Test Methods: Viruses
Susceptibility Test Methods: Viruses
Abstract
Testing for viral susceptibility, primarily via genotypic drug resistance mutation testing, is now standard practice for the management of viral infections for o...
Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy
Prophylactic antiviral therapy and all-cause mortality in cancer patients with hepatitis B e antigen-negative chronic hepatitis B virus infection receiving immunosuppressive therapy
Abstract
Background
The survival benefits of prophylactic antiviral therapy for cancer patients with hepatitis B e antigen (HBeA...
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Please cite this paper as: Borders‐Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and...
Investigating and Circumventing Mechanisms of Resistance to the Antibacterial Candidate, Niclosamide
Investigating and Circumventing Mechanisms of Resistance to the Antibacterial Candidate, Niclosamide
<p dir="ltr">The need for novel antibiotics is urgent, as mobilised resistance elements have emerged against even antibiotics of last resort and the productivity of the tradi...

